These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15605446)

  • 41. Sustained release characteristics of tablets prepared with mixed matrix of sodium carrageenan and chitosan: effect of polymer weight ratio, dissolution medium, and drug type.
    Bani-Jaber A; Al-Ghazawi M
    Drug Dev Ind Pharm; 2005 Mar; 31(3):241-7. PubMed ID: 15830719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
    Hussein Z; Friedman M
    Pharm Res; 1990 Nov; 7(11):1167-71. PubMed ID: 2293217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pectin/anhydrous dibasic calcium phosphate matrix tablets for in vitro controlled release of water-soluble drug.
    Mamani PL; Ruiz-Caro R; Veiga MD
    Int J Pharm; 2015 Oct; 494(1):235-43. PubMed ID: 26276258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carboxymethyl starch: Chitosan monolithic matrices containing diamine oxidase and catalase for intestinal delivery.
    Calinescu C; Mondovi B; Federico R; Ispas-Szabo P; Mateescu MA
    Int J Pharm; 2012 May; 428(1-2):48-56. PubMed ID: 22402476
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design and evaluation of a two-layer floating tablet for gastric retention using cisapride as a model drug.
    Wei Z; Yu Z; Bi D
    Drug Dev Ind Pharm; 2001 May; 27(5):469-74. PubMed ID: 11448055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioavailability of sulpiride tablet and capsule in dogs.
    Alam AS; Hagerman LM; Imondi AR
    Arch Int Pharmacodyn Ther; 1980 Oct; 247(2):180-9. PubMed ID: 7447564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein based tablets as reversible gelling systems for delayed release applications.
    Caillard R; Subirade M
    Int J Pharm; 2012 Nov; 437(1-2):130-6. PubMed ID: 22846408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of drug absorption in simulated theophylline overdose.
    Minton NA; Glucksman E; Henry JA
    Hum Exp Toxicol; 1995 Feb; 14(2):170-4. PubMed ID: 7779441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of in vitro dissolution of whole vs. half controlled-release theophylline tablets.
    Shah VP; Yamamoto LA; Schuirman D; Elkins J; Skelly JP
    Pharm Res; 1987 Oct; 4(5):416-9. PubMed ID: 3508552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Release kinetics of drug from different combined ratios of micropellets.
    Lin SY
    J Microencapsul; 1993; 10(3):319-22. PubMed ID: 8377089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of curdlan to controlled drug delivery. I. The preparation and evaluation of theophylline-containing curdlan tablets.
    Kanke M; Koda K; Koda Y; Katayama H
    Pharm Res; 1992 Mar; 9(3):414-8. PubMed ID: 1614977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential pharmacobezoar formation of large size extended-release tablets and their dissolution - an in vitro study.
    Hoegberg LCG; Refsgaard F; Pedersen SH; Personne M; Ullah S; Panagiotidis G; Petersen TS; Annas A
    Clin Toxicol (Phila); 2019 Apr; 57(4):271-281. PubMed ID: 30306811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Compressed donut-shaped tablets with zero-order release kinetics.
    Kim CJ
    Pharm Res; 1995 Jul; 12(7):1045-8. PubMed ID: 7494800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bioavailability and in vivo release behavior of controlled-release multiple-unit theophylline dosage forms in beagle dogs, cynomolgus monkeys, and göttingen minipigs.
    Ikegami K; Tagawa K; Osawa T
    J Pharm Sci; 2006 Sep; 95(9):1888-95. PubMed ID: 16850398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. D-optimal mixture design: optimization of ternary matrix blends for controlled zero-order drug release from oral dosage forms.
    El-Malah Y; Nazzal S; Khanfar NM
    Drug Dev Ind Pharm; 2006; 32(10):1207-18. PubMed ID: 17090443
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of pH on the in vitro dissolution and in vivo absorption of controlled-release theophylline in dogs.
    Vashi VI; Meyer MC
    J Pharm Sci; 1988 Sep; 77(9):760-4. PubMed ID: 3225770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preparation and evaluation of intragastric buoyant preparations.
    Machida Y; Inouye K; Tokumura T; Iwata M; Nagai T
    Drug Des Deliv; 1989 Mar; 4(2):155-61. PubMed ID: 2765108
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new drug delivery system using plasma-irradiated pharmaceutical aids. V. Controlled release of theophylline from plasma-irradiated double-compressed tablet composed of a wall material containing polybenzylmethacrylate.
    Ishikawa M; Noguchi T; Niwa J; Kuzuya M
    Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2215-20. PubMed ID: 8582024
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hot-melt coating technology. I. Influence of Compritol 888 Ato and granule size on theophylline release.
    Faham A; Prinderre P; Farah N; Eichler KD; Kalantzis G; Joachim J
    Drug Dev Ind Pharm; 2000 Feb; 26(2):167-76. PubMed ID: 10697753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.